Produção e avaliação de bacterina autógena contra meningite estreptococcica em suínos

• Autor(a) principal: Salgado, Carlos José Locatelli
• Data de Publicação: 2003
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: LOCUS Repositório Institucional da UFV
• Texto Completo: http://locus.ufv.br/handle/123456789/5168
• topic: Meningite estreptococcica; Streptococcus suis; Bacterina autógena; Streptococcal meningitis; Streptococcus suis; Autogenous bacterin; CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA::MEDICINA VETERINARIA PREVENTIVA

The present work was developed with the objective to determine the efficiency of an autogenous bacterin against Streptococcus suis serotype 2 and to test route and inoculation doses. Two experiments were accomplished with 64 animals in each experiment. In the Experiment I, 32 animals were vaccinated and 32 animals received placebo, being both groups challenged at the 60 days of age. In the Experiment II, the animals were divided in four groups: NVIP - 16 animals not vaccinated and challenged by the intraperitoneal route; VIP - 16 vaccinated animals and challenged by the intraperitoneal route; NVIV - 16 animals not vaccinated and challenged by the intravenous route; and VIV - 16 vaccinated animals and challenged by the intravenous route. All the groups were challenged at the 88 days of age. In the Experiment I, it was not possible to detect significant difference in the protection, clinical signs and lesions (P>0.05) among the groups not vaccinated and vaccinated. However, the isolation of S. suis and the average of the bacterial count was higher (P <0.01) in the group not vaccinated. The results observed in Experiment II in the groups NVIV and VIV presented protection, clinical signs and lesions similar (P>0.05), and the number of animals with positive isolation of S. suis and the average of the bacterial count was higher in the group NVIV (P<0.05). The groups NVIP and VIP presented significant difference for protection, clinical signs, lesions, number of positive isolations and average of the bacterial agent count (P <0.01). The intravenous challenge route was not appropriate for that experiment type and the intraperitoneal route presented favorable aspects. The vaccine was efficient for prevention of the infection with high virulent S. suis serotype 2, protecting the animals with an efficiency of 87.5 percent.